Lexicon Pharmaceuticals, Inc.

NASDAQ (USD): Lexicon Pharmaceuticals, Inc. (LXRX)

Last Price

1.77

Today's Change

+0.035 (2.009%)

Day's Change

1.73 - 1.84

Trading Volume

1,972,418

Profile
LXRX

Exchange:  NASDAQ Global Select NASDAQ Global Select

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Dr. Michael Exton Ph.D. Dr. Michael Exton Ph.D.

Full Time Employees:  285 285

IPO Date:  2000-04-07 2000-04-07

CIK:  0001062822 0001062822

ISIN:  US5288723027 US5288723027

CUSIP:  528872302 528872302

Beta:  1.29 1.29

Last Dividend:  0.00 0.00

Dcf Diff:  2.19 2.19

Dcf:  -0.39 -0.39

Description

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Address

2445 Technology Forest Boulevard,
The Woodlands, TX 77381, US

281 863 3000

http://www.lexpharma.com

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment